Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer

June 21, 2022 11:03 am

by Chris Ryan

The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.

The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in

Read more

Neoadjuvant Abemaciclib and Fulvestrant Facilitates High Complete Gross Resection Rate in Low-Grade Serous Cancer

June 15, 2022 12:04 pm

by Caroline Seymour

The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.

The combination

Read more

MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

Frontline Bevacizumab Beneficial for Ovarian Clear Cell Carcinoma, Retrospective Analysis Shows

June 6, 2022 9:49 am

by Lisa Astor

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.

A retrospective analysis

Read more

Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer

April 27, 2022 12:40 pm

by Matthew Stenger

In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more

Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian Cancer

April 18, 2022 12:28 pm

by Lindsay Fischer

New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.

Patients with BRCA1/–mutated, platinum-sensitive, recurrent ovarian cancer who needed to reduce

Read more

Relacorilant/Nab-Paclitaxel Combo Improves OS in Recurrent, Platinum-Resistant Ovarian Cancer

April 5, 2022 11:17 am

by Kristi Rosa

The addition of relacorilant to nab-paclitaxel improved overall survival compared with nab-paclitaxel alone in patients with recurrent, platinum-resistant ovarian cancer.

The addition of relacorilant to nab-paclitaxel (Abraxane) improved overall survival (OS) compared with nab-paclitaxel alone in patients

Read more

Maintenance Rucaparib Significantly Improves PFS in Phase 3 ATHENA-MONO Trial for Advanced Ovarian Cancer

March 31, 2022 10:44 am

by Ariana Pelosci

A significant improvement in progression-free survival was observed in the phase 3 ATHENA-MONO trial with first-line maintenance rucaparib vs placebo in patients with advanced ovarian cancer.

Progression-free survival (PFS) was significantly improved with first-line rucaparib (Rubraca) as

Read more

Ovarian Cancer Patients in PARP Inhibitor Trials Don’t Reflect Real-World Population

February 25, 2022 11:33 am

by Jonathan Goodman, MPhil

Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.

Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more

Ovarian Cancer and a New Era for Clinical Trials

April 20, 2021 9:00 am

At Clearity we are intent on bringing the future of ovarian cancer treatment to women today. It’s exciting to have the opportunity to work with other organizations who share our vision. Teckro’s goal is to make clinical trials more accessible, Read more

The Stressful Conclusion of a Clinical Trial

November 9, 2020 9:00 am

By 

When I learned this summer that the clinical trial of the cancer drug that seems to be keeping me alive had unexpectedly shut down, I discovered the murky rules governing drug trials and the stressful confusion they … Read more

Improvements to Cancer Clinical Trials After COVID-19 Wreckage

November 3, 2020 3:00 pm

By Kate Johnson

As the COVID-19 pandemic rolled across North America earlier this year, cancer clinics shut their doors, patients stayed home, and oncology researchers contemplated an unthinkable setback as laboratory closures and trial freezes threatened the demise of years … Read more

Most Cancer Patients Would Join a Clinical Trial if Offered the Chance

October 20, 2020 4:00 pm

By Anne Harding

New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials.

Overall, 55% of patients offered trial participation agreed to enroll, and white and Black patients agreed to … Read more

Large Genomics Study Points the Way to Future Cancer Clinical Trials

October 14, 2020 11:00 am

By Angus Liu

Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more

First-in-Human Study of RAF Family Kinase Inhibitor Lifirafenib in Solid Tumors

March 27, 2020 12:30 pm

By Matthew Stenger

In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or … Read more

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 26, 2020 10:00 am

By Jason M. Broderick

An independent panel determined that the investigational agent VB-111 (ofranergene obadenovec) met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without … Read more